Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.51 |
| ▸ | RPS6KB1 | P23443 | 7/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4482160 | 0.90 | AURKA (0.46) | AURKARPS6KB1HIF1ABRD4HPGDS | |
| SCHEMBL4482214 | 0.87 | AURKA (0.49) | AURKARPS6KB1HIF1APDPK1AURKB | |
| SCHEMBL4489700 | 0.87 | HIF1A (0.58) | AURKARPS6KB1HIF1APDPK1AURKB | |
| SCHEMBL4500058 | 0.85 | SMN1; SMN2 (0.53) | AURKARPS6KB1HIF1ASMN1; SMN2HPGDS | |
| SCHEMBL4489260 | 0.82 | HPGDS (0.55) | SMN1; SMN2HPGDSKDM4EMAPT | |
| SCHEMBL4496183 | 0.81 | LMNA (0.46) | AURKARPS6KB1HIF1ASMN1; SMN2HPGDS | |
| SCHEMBL4501469 | 0.81 | APEX1 (0.49) | SMN1; SMN2HPGDSMEN1KMT2A | |
| SCHEMBL4484547 | 0.81 | APP (0.48) | AURKARPS6KB1HIF1ASMN1; SMN2HPGDS | |
| SCHEMBL4493680 | 0.81 | MITF (0.56) | AURKARPS6KB1KDM4EMEN1KMT2A | |
| SCHEMBL4489494 | 0.79 | HIF1A (0.60) | AURKAHIF1ASMN1; SMN2HPGDSKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | claimed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | claimed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | claimed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | claimed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | claimed |
| US-7482455-B2 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-01-27 | — | — | US | disclosed |
| EP-1556379-A4 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-06-13 | — | — | EP | disclosed |
| US-20060106058-A1 | Chemical compounds | BURGESS JOELLE L | 2006-05-18 | — | — | US | disclosed |
| EP-1556379-A2 | CHEMICAL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004034985-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106058-A1 | Chemical compounds | YARS1, DAPK3, NEK3 | AURKA 235/4885RPS6KB1 296/4885HIF1A 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.